HIV Infections Clinical Trial
To define the incidence and prevalence of AIDS-associated cardiomyopathy. Also, to conduct immunopathology and serologic studies in endomyocardial biopsies and autopsy tissues.
BACKGROUND:
In 1988, the leading cause of death in AIDS patients was respiratory mechanisms might have
played a significant role in its pathogenesis.
The project was part of an Institute-initiated study on AIDS-Associated Heart Disease in
Adults. The concept was approved by the National Heart, Lung, and Blood Advisory Council in
September 1987. The Request for Applications was also released in September 1987. Awards
were made in July 1988.
DESIGN NARRATIVE:
The prevalence study was one of three subprojects with the common failure due to chronic
opportunistic pulmonary infection, primarily Pneumocystis carinii pneumonia. Drugs such as
azidothymidine (AZT) and trimetrexate showed some effectiveness in prolonging the lives of
some AIDS patients. With increased survival, it was believed that cardiac diseases might
well become an important complication of AIDs. Reports described a syndrome of rapidly
progressive cardiomyopathy associated with AIDS. The etiology of AIDS-associated
cardiomyopathy was yet unknown although immunologic theme of the immunopathogenesis of
AIDS-associated cardiomyopathy. The other two subprojects dealt with immunopathology studies
in endomyocardial biopsies and autopsy tissues and serologic studies. The AIDS Clinical
Research Center at Johns Hopkins Hospital served as the source of patients. All patients
underwent serologic testing and echocardiography at time of entry and at six and twelve
months. The screening electrocardiogram identified 40 to 50 patients per year with
AIDS-associated cardiomyopathy. Approximately 30 patients per year had no contraindications
for endomyocardial biopsy. Comprehensive tissue studies and cellular immune studies were
performed on the cohort and autopsies, if possible. Immunohistochemical techniques and in
situ hybridization of biopsy and autopsy material were used to determine if AIDS-associated
cardiomyopathy was associated with HIV infection of the heart or with some other viral or
opportunistic non-viral infection. Indirect immunofluorescence and a Western immunoblotting
assay using patient sera determined the prevalence of heart autoimmunity.
The study completion date listed in this record was obtained from the "End Date" entered in
the Protocol Registration and Results System (PRS) record.
;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |